Quantification and composition of pharmaceutical waste in New Zealand.
Pharmaceutical waste
Waste production
Waste stream composition
Journal
Journal of material cycles and waste management
ISSN: 1611-8227
Titre abrégé: J Mater Cycles Waste Manag
Pays: Japan
ID NLM: 101768822
Informations de publication
Date de publication:
2022
2022
Historique:
received:
19
11
2021
accepted:
29
03
2022
pubmed:
17
5
2022
medline:
17
5
2022
entrez:
16
5
2022
Statut:
ppublish
Résumé
This study aimed to quantify the amount of pharmaceutical waste produced in New Zealand, and determine the composition of pharmaceutical waste from community pharmacies in Auckland, New Zealand. Pharmaceutical waste collected in New Zealand is increasing, peaking at 542 tonne in 2019. Pharmaceutical waste collected from hospitals and pharmacies in Auckland increased by more than fourfold from 2016 to 2020. An audit of the types of pharmaceutical waste collected from community pharmacies revealed that the most common classes of drugs identified in this waste stream belonged to the nervous system, cardiovascular system and alimentary tract, and metabolism. Following examination of the contents of 12 pharmaceutical waste bins, 475 different pharmaceutical products were identified, highlighting the breadth of drugs in this waste stream. A range of dosage forms and hence materials were identified, which could present challenges for future waste treatment approaches. Hazardous drugs were identified including cytotoxic compounds, which should go into a separate waste stream for incineration. There is a need for similar data to be collected from multiple sites to fully appreciate the magnitude and composition of pharmaceutical waste. This will allow for the suitability of current practices for managing this hazardous waste stream to be evaluated.
Identifiants
pubmed: 35570848
doi: 10.1007/s10163-022-01410-z
pii: 1410
pmc: PMC9085561
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1603-1611Informations de copyright
© The Author(s) 2022.
Déclaration de conflit d'intérêts
Conflict of interestNone.
Références
Pharm World Sci. 2005 Aug;27(4):296-9
pubmed: 16228627
J Public Health (Oxf). 2007 Sep;29(3):258-62
pubmed: 17579236
Waste Manag. 2012 Jul;32(7):1442-52
pubmed: 22365264
Subst Abuse Treat Prev Policy. 2017 Aug 15;12(1):36
pubmed: 28810899
Aust Prescr. 2018 Jun;41(3):78-81
pubmed: 29922002
Am J Health Syst Pharm. 2020 Mar 24;77(7):574-582
pubmed: 32050015
Environ Int. 2009 Aug;35(6):952-5
pubmed: 19423167
Environ Dev Sustain. 2021;23(5):7951-7960
pubmed: 32863738
N Z Med J. 2020 Apr 24;133(1513):61-72
pubmed: 32325469
BMC Public Health. 2018 Aug 17;18(1):1026
pubmed: 30119656
Expert Rev Anti Infect Ther. 2020 Aug;18(8):697-699
pubmed: 32281427
J Prim Health Care. 2011 Sep 01;3(3):197-203
pubmed: 21892421
Community Dent Oral Epidemiol. 1997 Aug;25(4):328-31
pubmed: 9332812
J Environ Manage. 2019 Mar 1;233:649-659
pubmed: 30605791
J Hazard Mater. 2009 Mar 15;162(2-3):730-5
pubmed: 18599201
J Pharm Policy Pract. 2017 Dec 07;10:38
pubmed: 29234498